{"id":43399,"date":"2020-12-09T14:57:33","date_gmt":"2020-12-09T12:57:33","guid":{"rendered":"https:\/\/newserver.fyb.de\/emergence-therapeutics-receives-follow-on-seed-round\/"},"modified":"2020-12-09T14:57:33","modified_gmt":"2020-12-09T12:57:33","slug":"emergence-therapeutics-receives-follow-on-seed-round","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/","title":{"rendered":"Emergence Therapeutics receives follow on seed&nbsp;round"},"content":{"rendered":"<p>D\u00fcssel\u00addorf, Germany, Decem\u00adber 9, 2020 \u2014 ARQIS advi\u00adsed Emer\u00adgence Thera\u00adpeu\u00adtics AG, a Euro\u00adpean life science startup, on its exten\u00added follow-on seed finan\u00adcing round. The capi\u00adtal comes from a consor\u00adtium of leading Euro\u00adpean inves\u00adtors, consis\u00adting of <strong>Bpifrance (through its Inno\u00adBio 2 Fund), Gr\u00fcn\u00adder\u00adfonds Ruhr, Heidel\u00adberg Pharma Rese\u00adarch GmbH, High-Tech Gr\u00fcn\u00adder\u00adfonds, idin\u00advest Part\u00adners, Kurma Part\u00adners and NRW.Bank<\/strong>. The follow-on seed round was led by High-Tech Gr\u00fcn\u00adder\u00adfonds and included support from the first pillar of the German govern\u00admen\u00adt\u2019s \u20ac2 billion package of measu\u00adres for startups.<\/p>\n<p>Jack Elands, CEO of Emer\u00adgence Thera\u00adpeu\u00adtics, said, \u201cWe are grateful for the contin\u00adued support from our inves\u00adtors at this seed stage. Proceeds from the follow-on seed round will be used to advance our deve\u00adlo\u00adp\u00adment programs focu\u00adsed on Nectin\u20114 as a target protein \u2014 an incre\u00adasingly important and clini\u00adcally vali\u00adda\u00adted thera\u00adpeu\u00adtic target across a broad spec\u00adtrum of cancers. In addi\u00adtion, the funding will enable us to acce\u00adle\u00adrate work on addi\u00adtio\u00adnal programs and expand our ADC tool\u00adkit to include addi\u00adtio\u00adnal highly inno\u00adva\u00adtive linker payload technologies.\u201d<\/p>\n<p>Emer\u00adgence Thera\u00adpeu\u00adtics is a biophar\u00admaceu\u00adti\u00adcal company deve\u00adlo\u00adping novel anti\u00adbody-drug conju\u00adga\u00adtes (ADCs) for the treat\u00adment of cancers with high unmet medi\u00adcal need. Its lead program uses inno\u00adva\u00adtive linker and payload tech\u00adno\u00adlogy to address Nectin\u20114, an important and vali\u00adda\u00adted target for a broad range of cancers. In addi\u00adtion, the company is actively explo\u00adring and deve\u00adlo\u00adping oppor\u00adtu\u00adni\u00adties to deve\u00adlop addi\u00adtio\u00adnal best- or first-in-class ADCs based on thera\u00adpeu\u00adtic need. Emer\u00adgence is based in Duis\u00adburg, Germany, and has a subsi\u00addiary in Marseille, France.<\/p>\n<p>The ARQIS team led by part\u00adner Dr. Chris\u00adtof Alex\u00adan\u00adder Schnei\u00adder alre\u00adady star\u00adted advi\u00adsing Emer\u00adgence Thera\u00adpeu\u00adtics in 2019, when the startup was foun\u00added via a colla\u00adbo\u00adra\u00adtion between (inter alia) the Univer\u00adsity of Marseille and Heidel\u00adberg Pharma AG. As a result, the firm orga\u00adni\u00adzed the prece\u00adding finan\u00adcing&nbsp;round.<\/p>\n<p><strong>Advi\u00adsor Emer\u00adgence Thera\u00adpeu\u00adtics: ARQIS Attor\u00adneys at&nbsp;Law<br>\n<\/strong><br>\nDr. Chris\u00adtof Alex\u00adan\u00adder Schnei\u00adder (Lead; Tran\u00adsac\u00adtions; D\u00fcssel\u00addorf), Dr. Mauritz von Einem (Tax Law); Asso\u00adciate: Louisa Theresa Graf (Tran\u00adsac\u00adtions; both Munich)<br>\nNiit\u00adv\u00e4li (Frank\u00adfurt): Evelyn Niit\u00adv\u00e4li (Anti\u00adtrust)<\/p>\n<p><strong>About ARQIS<\/strong><\/p>\n<p>ARQIS Attor\u00adneys at Law is an inde\u00adpen\u00addent busi\u00adness law firm opera\u00adting in Germany and Japan. The firm was foun\u00added in 2006 in D\u00fcssel\u00addorf, Munich and Tokyo. Around 55 profes\u00adsio\u00adnals advise dome\u00adstic and foreign compa\u00adnies at the highest level on German and Japa\u00adnese busi\u00adness law. For more infor\u00adma\u00adtion, visit www.arqis.com.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00fcssel\u00addorf, Germany, Decem\u00adber 9, 2020 \u2014 ARQIS advi\u00adsed Emer\u00adgence Thera\u00adpeu\u00adtics AG, a Euro\u00adpean life science startup, on its exten\u00added follow-on seed finan\u00adcing round. The capi\u00adtal comes from a consor\u00adtium of leading Euro\u00adpean inves\u00adtors, consis\u00adting of Bpifrance (through its Inno\u00adBio 2 Fund), Gr\u00fcn\u00adder\u00adfonds Ruhr, Heidel\u00adberg Pharma Rese\u00adarch GmbH, High-Tech Gr\u00fcn\u00adder\u00adfonds, idin\u00advest Part\u00adners, Kurma Part\u00adners and NRW.Bank. [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":36427,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1369,1372,1373],"tags":[],"class_list":["post-43399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"D\u00fcssel\u00addorf, Germany, Decem\u00adber 9, 2020 \u2014 ARQIS advi\u00adsed Emer\u00adgence Thera\u00adpeu\u00adtics AG, a Euro\u00adpean life science startup, on its exten\u00added follow-on seed finan\u00adcing round. The capi\u00adtal comes from a consor\u00adtium of leading Euro\u00adpean inves\u00adtors, consis\u00adting of Bpifrance (through its Inno\u00adBio 2 Fund), Gr\u00fcn\u00adder\u00adfonds Ruhr, Heidel\u00adberg Pharma Rese\u00adarch GmbH, High-Tech Gr\u00fcn\u00adder\u00adfonds, idin\u00advest Part\u00adners, Kurma Part\u00adners and NRW.Bank. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T12:57:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"320\" \/>\n\t<meta property=\"og:image:height\" content=\"213\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Emergence Therapeutics receives follow on seed&nbsp;round\",\"datePublished\":\"2020-12-09T12:57:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\"},\"wordCount\":384,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers, tax consultants, auditors\",\"Investors\",\"Consultant\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\",\"url\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\",\"name\":\"Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg\",\"datePublished\":\"2020-12-09T12:57:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg\",\"width\":320,\"height\":213},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emergence Therapeutics receives follow on seed&nbsp;round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/","og_locale":"en_US","og_type":"article","og_title":"Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook","og_description":"D\u00fcssel\u00addorf, Germany, Decem\u00adber 9, 2020 \u2014 ARQIS advi\u00adsed Emer\u00adgence Thera\u00adpeu\u00adtics AG, a Euro\u00adpean life science startup, on its exten\u00added follow-on seed finan\u00adcing round. The capi\u00adtal comes from a consor\u00adtium of leading Euro\u00adpean inves\u00adtors, consis\u00adting of Bpifrance (through its Inno\u00adBio 2 Fund), Gr\u00fcn\u00adder\u00adfonds Ruhr, Heidel\u00adberg Pharma Rese\u00adarch GmbH, High-Tech Gr\u00fcn\u00adder\u00adfonds, idin\u00advest Part\u00adners, Kurma Part\u00adners and NRW.Bank. [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-12-09T12:57:33+00:00","og_image":[{"width":320,"height":213,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Emergence Therapeutics receives follow on seed&nbsp;round","datePublished":"2020-12-09T12:57:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/"},"wordCount":384,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg","articleSection":["General","Featured","News","Lawyers, tax consultants, auditors","Investors","Consultant","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/","url":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/","name":"Emergence Therapeutics receives follow on seed round - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg","datePublished":"2020-12-09T12:57:33+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/12\/a-virus-3.jpeg","width":320,"height":213},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/emergence-therapeutics-receives-follow-on-seed-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Emergence Therapeutics receives follow on seed&nbsp;round"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43399"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/36427"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}